Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Esophageal Neoplasms | 45 | 2024 | 1658 | 5.690 |
Why?
|
Stomach Neoplasms | 33 | 2024 | 1457 | 3.700 |
Why?
|
Esophagogastric Junction | 20 | 2024 | 347 | 3.130 |
Why?
|
Adenocarcinoma | 43 | 2024 | 6341 | 2.520 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 56 | 2024 | 11733 | 2.070 |
Why?
|
Cisplatin | 16 | 2022 | 1652 | 1.030 |
Why?
|
Camptothecin | 17 | 2017 | 591 | 1.000 |
Why?
|
Fluorouracil | 23 | 2024 | 1642 | 0.990 |
Why?
|
Platinum | 1 | 2022 | 220 | 0.740 |
Why?
|
Receptor, erbB-2 | 5 | 2024 | 2553 | 0.670 |
Why?
|
Carcinoma, Squamous Cell | 10 | 2023 | 4021 | 0.610 |
Why?
|
Neoadjuvant Therapy | 10 | 2024 | 2827 | 0.590 |
Why?
|
Gastrointestinal Neoplasms | 7 | 2023 | 955 | 0.570 |
Why?
|
Leucovorin | 13 | 2022 | 643 | 0.520 |
Why?
|
Clinical Protocols | 1 | 2021 | 1436 | 0.480 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2016 | 321 | 0.460 |
Why?
|
Esophagectomy | 5 | 2021 | 469 | 0.440 |
Why?
|
Gastrectomy | 3 | 2021 | 671 | 0.400 |
Why?
|
Pancreatic Neoplasms | 12 | 2024 | 5366 | 0.400 |
Why?
|
Colonic Neoplasms | 8 | 2017 | 2527 | 0.390 |
Why?
|
Antineoplastic Agents | 14 | 2020 | 13632 | 0.380 |
Why?
|
Neuroendocrine Tumors | 7 | 2022 | 642 | 0.380 |
Why?
|
Organoplatinum Compounds | 8 | 2019 | 407 | 0.360 |
Why?
|
Paclitaxel | 8 | 2024 | 1730 | 0.320 |
Why?
|
Aged | 69 | 2024 | 169288 | 0.290 |
Why?
|
Research Design | 2 | 2021 | 6180 | 0.290 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 3 | 2024 | 212 | 0.290 |
Why?
|
Colorectal Neoplasms | 14 | 2023 | 6919 | 0.280 |
Why?
|
Middle Aged | 68 | 2024 | 220853 | 0.260 |
Why?
|
Surgery Department, Hospital | 1 | 2007 | 176 | 0.250 |
Why?
|
Aged, 80 and over | 40 | 2024 | 58952 | 0.250 |
Why?
|
Deoxycytidine | 11 | 2024 | 878 | 0.250 |
Why?
|
Disease-Free Survival | 12 | 2017 | 6819 | 0.240 |
Why?
|
Carboplatin | 3 | 2022 | 793 | 0.230 |
Why?
|
Male | 76 | 2024 | 360693 | 0.230 |
Why?
|
Neoplasm Staging | 16 | 2021 | 11119 | 0.230 |
Why?
|
Humans | 109 | 2024 | 761208 | 0.220 |
Why?
|
Combined Modality Therapy | 10 | 2021 | 8519 | 0.220 |
Why?
|
Survival Rate | 13 | 2021 | 12728 | 0.220 |
Why?
|
Epirubicin | 3 | 2021 | 81 | 0.220 |
Why?
|
Adult | 59 | 2024 | 221119 | 0.220 |
Why?
|
Female | 76 | 2024 | 392544 | 0.220 |
Why?
|
Taxoids | 3 | 2020 | 668 | 0.220 |
Why?
|
Antineoplastic Agents, Phytogenic | 3 | 2006 | 620 | 0.210 |
Why?
|
Neoplasm Metastasis | 15 | 2024 | 4909 | 0.210 |
Why?
|
Antibodies, Monoclonal | 11 | 2024 | 9187 | 0.200 |
Why?
|
Hypoalbuminemia | 1 | 2023 | 86 | 0.200 |
Why?
|
Drug Administration Schedule | 11 | 2016 | 4851 | 0.200 |
Why?
|
Granuloma, Foreign-Body | 1 | 2021 | 42 | 0.190 |
Why?
|
Appendiceal Neoplasms | 1 | 2023 | 155 | 0.190 |
Why?
|
Anus Neoplasms | 3 | 2012 | 330 | 0.180 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2000 | 70 | 0.180 |
Why?
|
Treatment Outcome | 32 | 2024 | 64681 | 0.170 |
Why?
|
Keratins | 1 | 2021 | 498 | 0.170 |
Why?
|
Barrett Esophagus | 1 | 2004 | 492 | 0.170 |
Why?
|
Rectal Neoplasms | 3 | 2015 | 1156 | 0.170 |
Why?
|
Quinazolines | 9 | 2012 | 1371 | 0.170 |
Why?
|
Colectomy | 1 | 2004 | 686 | 0.160 |
Why?
|
Dacarbazine | 3 | 2012 | 559 | 0.160 |
Why?
|
Lymph Node Excision | 2 | 2020 | 1270 | 0.160 |
Why?
|
Claudins | 3 | 2024 | 117 | 0.160 |
Why?
|
Interleukin-1beta | 1 | 2024 | 1002 | 0.160 |
Why?
|
Nausea | 2 | 2024 | 678 | 0.150 |
Why?
|
Liver Neoplasms | 6 | 2014 | 4309 | 0.150 |
Why?
|
Neutropenia | 1 | 2023 | 885 | 0.150 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2020 | 422 | 0.140 |
Why?
|
Peritoneal Neoplasms | 1 | 2023 | 710 | 0.140 |
Why?
|
Maximum Tolerated Dose | 6 | 2012 | 883 | 0.130 |
Why?
|
Deglutition Disorders | 3 | 2016 | 627 | 0.130 |
Why?
|
Double-Blind Method | 5 | 2023 | 12341 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2019 | 546 | 0.130 |
Why?
|
Administration, Oral | 6 | 2016 | 4015 | 0.130 |
Why?
|
Quality-Adjusted Life Years | 1 | 2022 | 1723 | 0.130 |
Why?
|
Anorexia | 1 | 2016 | 152 | 0.130 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2018 | 2024 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2023 | 1052 | 0.120 |
Why?
|
Carcinoma | 2 | 2020 | 2330 | 0.120 |
Why?
|
Survival Analysis | 13 | 2021 | 10088 | 0.120 |
Why?
|
Microsatellite Instability | 3 | 2022 | 716 | 0.120 |
Why?
|
Guidelines as Topic | 2 | 2019 | 1385 | 0.120 |
Why?
|
Lymphatic Metastasis | 2 | 2021 | 2913 | 0.120 |
Why?
|
Medical Oncology | 5 | 2023 | 2320 | 0.120 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2024 | 2915 | 0.120 |
Why?
|
Radiopharmaceuticals | 2 | 2018 | 2683 | 0.120 |
Why?
|
Alcohol Drinking | 2 | 2004 | 4027 | 0.120 |
Why?
|
Triazoles | 1 | 2020 | 902 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2017 | 9278 | 0.110 |
Why?
|
Sirolimus | 2 | 2013 | 1540 | 0.110 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2006 | 646 | 0.110 |
Why?
|
Laparoscopy | 1 | 2004 | 2035 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1616 | 0.100 |
Why?
|
Indoles | 2 | 2011 | 1830 | 0.100 |
Why?
|
Angiogenesis Inhibitors | 4 | 2014 | 2047 | 0.100 |
Why?
|
beta Karyopherins | 1 | 2011 | 46 | 0.090 |
Why?
|
Palliative Care | 4 | 2017 | 3599 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2021 | 3512 | 0.090 |
Why?
|
Carcinoma, Hepatocellular | 3 | 2009 | 2293 | 0.090 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2012 | 748 | 0.090 |
Why?
|
Informed Consent | 1 | 2017 | 1008 | 0.090 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2024 | 858 | 0.090 |
Why?
|
Enzyme Inhibitors | 1 | 2000 | 3702 | 0.090 |
Why?
|
Treatment Failure | 1 | 2016 | 2643 | 0.090 |
Why?
|
Hydroxychloroquine | 1 | 2014 | 426 | 0.090 |
Why?
|
Preoperative Care | 2 | 2013 | 2241 | 0.090 |
Why?
|
Phenylurea Compounds | 1 | 2013 | 529 | 0.080 |
Why?
|
Cost-Benefit Analysis | 1 | 2022 | 5493 | 0.080 |
Why?
|
Immunoconjugates | 1 | 2017 | 963 | 0.080 |
Why?
|
Disease Progression | 7 | 2017 | 13511 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 6 | 2020 | 6486 | 0.080 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 2009 | 83 | 0.080 |
Why?
|
Quality of Life | 4 | 2024 | 13367 | 0.080 |
Why?
|
Carcinoid Tumor | 2 | 2009 | 225 | 0.070 |
Why?
|
Genomic Instability | 1 | 2012 | 709 | 0.070 |
Why?
|
Time Factors | 7 | 2021 | 39957 | 0.070 |
Why?
|
Patient Participation | 1 | 2017 | 1445 | 0.070 |
Why?
|
Biliary Tract Neoplasms | 1 | 2009 | 185 | 0.070 |
Why?
|
Tubulin | 1 | 2011 | 692 | 0.070 |
Why?
|
Quinolines | 1 | 2013 | 764 | 0.070 |
Why?
|
Follow-Up Studies | 5 | 2019 | 39126 | 0.070 |
Why?
|
Patient Education as Topic | 1 | 2017 | 2317 | 0.070 |
Why?
|
Oxonic Acid | 1 | 2006 | 31 | 0.070 |
Why?
|
Tegafur | 1 | 2006 | 39 | 0.070 |
Why?
|
Autophagy | 1 | 2014 | 1327 | 0.070 |
Why?
|
Endostatins | 1 | 2006 | 168 | 0.060 |
Why?
|
Digestive System Neoplasms | 1 | 2006 | 83 | 0.060 |
Why?
|
Prognosis | 5 | 2019 | 29687 | 0.060 |
Why?
|
Young Adult | 8 | 2024 | 59221 | 0.060 |
Why?
|
Geriatric Assessment | 1 | 2013 | 1409 | 0.060 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2011 | 2058 | 0.060 |
Why?
|
Vinblastine | 1 | 2006 | 488 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5333 | 0.060 |
Why?
|
Video-Assisted Surgery | 1 | 2004 | 51 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5694 | 0.060 |
Why?
|
Recombinant Proteins | 3 | 2023 | 6504 | 0.060 |
Why?
|
Pheochromocytoma | 1 | 2006 | 328 | 0.050 |
Why?
|
Esophageal Fistula | 1 | 2003 | 60 | 0.050 |
Why?
|
Terminally Ill | 1 | 2005 | 240 | 0.050 |
Why?
|
Data Collection | 1 | 2013 | 3320 | 0.050 |
Why?
|
Retrospective Studies | 9 | 2023 | 80674 | 0.050 |
Why?
|
Pyrroles | 1 | 2009 | 1124 | 0.050 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2012 | 2820 | 0.050 |
Why?
|
Boronic Acids | 1 | 2006 | 915 | 0.050 |
Why?
|
Radiotherapy Dosage | 2 | 2021 | 2897 | 0.050 |
Why?
|
CpG Islands | 1 | 2007 | 1190 | 0.050 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2006 | 339 | 0.050 |
Why?
|
Gallbladder Neoplasms | 1 | 2004 | 189 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8536 | 0.050 |
Why?
|
Human papillomavirus 16 | 1 | 2024 | 267 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2022 | 3493 | 0.050 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2023 | 2054 | 0.050 |
Why?
|
Quality Improvement | 1 | 2017 | 3808 | 0.050 |
Why?
|
Protein Kinases | 1 | 2008 | 1607 | 0.050 |
Why?
|
Survival | 1 | 2021 | 161 | 0.050 |
Why?
|
Vomiting | 1 | 2024 | 650 | 0.050 |
Why?
|
Practice Guidelines as Topic | 3 | 2015 | 7400 | 0.050 |
Why?
|
Salvage Therapy | 1 | 2007 | 1264 | 0.050 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3873 | 0.050 |
Why?
|
Pyrazines | 1 | 2006 | 1202 | 0.050 |
Why?
|
North America | 1 | 2024 | 1284 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2024 | 10218 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2023 | 629 | 0.040 |
Why?
|
Albumins | 1 | 2023 | 575 | 0.040 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2006 | 732 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2023 | 385 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2009 | 10756 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 636 | 0.040 |
Why?
|
Antibodies, Bispecific | 1 | 2022 | 196 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2024 | 1702 | 0.040 |
Why?
|
Edema | 1 | 2023 | 764 | 0.040 |
Why?
|
Nutrition Surveys | 1 | 2005 | 1723 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2000 | 628 | 0.040 |
Why?
|
Prospective Studies | 3 | 2018 | 54435 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2023 | 610 | 0.040 |
Why?
|
DNA, Neoplasm | 1 | 2023 | 1743 | 0.040 |
Why?
|
Isotretinoin | 1 | 1999 | 134 | 0.040 |
Why?
|
Infusions, Intravenous | 3 | 2009 | 2217 | 0.040 |
Why?
|
Pyridones | 1 | 2023 | 809 | 0.040 |
Why?
|
DNA, Viral | 1 | 2024 | 2195 | 0.040 |
Why?
|
Pamphlets | 1 | 2017 | 71 | 0.030 |
Why?
|
Positron-Emission Tomography | 2 | 2012 | 6585 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2006 | 2426 | 0.030 |
Why?
|
Clinical Trials as Topic | 2 | 2004 | 8003 | 0.030 |
Why?
|
Gastroesophageal Reflux | 1 | 2003 | 821 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1838 | 0.030 |
Why?
|
Risk Assessment | 5 | 2021 | 24021 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2022 | 2509 | 0.030 |
Why?
|
Gene Amplification | 1 | 2020 | 1084 | 0.030 |
Why?
|
Retreatment | 1 | 2017 | 598 | 0.030 |
Why?
|
ras Proteins | 2 | 2014 | 1055 | 0.030 |
Why?
|
Oxaloacetates | 1 | 2014 | 5 | 0.030 |
Why?
|
Interferon-alpha | 1 | 1999 | 907 | 0.030 |
Why?
|
Risk Factors | 5 | 2021 | 74239 | 0.030 |
Why?
|
China | 1 | 2020 | 2374 | 0.030 |
Why?
|
Neoplasms | 2 | 2017 | 22140 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2020 | 5300 | 0.030 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2009 | 617 | 0.030 |
Why?
|
Feeding Behavior | 1 | 2005 | 3183 | 0.030 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2024 | 1726 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 166 | 0.030 |
Why?
|
DNA Methylation | 1 | 2007 | 4384 | 0.030 |
Why?
|
Genomics | 2 | 2023 | 5828 | 0.030 |
Why?
|
Video Recording | 1 | 2017 | 965 | 0.020 |
Why?
|
United States | 4 | 2020 | 72339 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2024 | 3634 | 0.020 |
Why?
|
Clinical Competence | 1 | 2007 | 4788 | 0.020 |
Why?
|
Blood Loss, Surgical | 1 | 2015 | 637 | 0.020 |
Why?
|
GTP Phosphohydrolases | 1 | 2014 | 517 | 0.020 |
Why?
|
Mutation | 3 | 2024 | 30002 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4574 | 0.020 |
Why?
|
Patient Compliance | 1 | 2021 | 2688 | 0.020 |
Why?
|
Thalidomide | 2 | 2006 | 885 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 2 | 2023 | 5662 | 0.020 |
Why?
|
Perioperative Care | 1 | 2018 | 1037 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2024 | 7571 | 0.020 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2012 | 355 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2014 | 1075 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 129 | 0.020 |
Why?
|
Medicare | 1 | 2007 | 6773 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 1998 | 6304 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 2 | 2014 | 4513 | 0.020 |
Why?
|
Length of Stay | 1 | 2021 | 6417 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2009 | 454 | 0.020 |
Why?
|
Smoking | 1 | 2003 | 9055 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2813 | 0.020 |
Why?
|
Demography | 1 | 2011 | 1641 | 0.020 |
Why?
|
Digestive System Surgical Procedures | 1 | 2011 | 571 | 0.020 |
Why?
|
Carcinoma, Islet Cell | 1 | 2006 | 21 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1746 | 0.020 |
Why?
|
Upper Gastrointestinal Tract | 1 | 2006 | 46 | 0.020 |
Why?
|
Lymphocytes | 1 | 2014 | 2603 | 0.020 |
Why?
|
Disease Management | 1 | 2017 | 2507 | 0.020 |
Why?
|
Tocopherols | 1 | 2005 | 44 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2012 | 1767 | 0.020 |
Why?
|
Incidence | 1 | 2003 | 21365 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2012 | 2706 | 0.020 |
Why?
|
Self Administration | 1 | 2006 | 387 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2006 | 672 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2023 | 22127 | 0.010 |
Why?
|
Radiotherapy | 1 | 2011 | 1499 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2005 | 318 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2010 | 1624 | 0.010 |
Why?
|
Gene Deletion | 1 | 2012 | 2658 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 361 | 0.010 |
Why?
|
Pilot Projects | 1 | 2018 | 8642 | 0.010 |
Why?
|
Continuity of Patient Care | 1 | 2011 | 1069 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2015 | 5250 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 8530 | 0.010 |
Why?
|
Age Factors | 1 | 2021 | 18384 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2009 | 2928 | 0.010 |
Why?
|
Piperidines | 1 | 2012 | 1656 | 0.010 |
Why?
|
Massachusetts | 2 | 2007 | 8837 | 0.010 |
Why?
|
DNA Copy Number Variations | 1 | 2012 | 2024 | 0.010 |
Why?
|
Patient Selection | 1 | 2015 | 4246 | 0.010 |
Why?
|
Patient Readmission | 1 | 2017 | 3265 | 0.010 |
Why?
|
Animals | 3 | 2023 | 168079 | 0.010 |
Why?
|
Carotenoids | 1 | 2005 | 621 | 0.010 |
Why?
|
Nutrition Assessment | 1 | 2005 | 727 | 0.010 |
Why?
|
Mice | 2 | 2023 | 81326 | 0.010 |
Why?
|
Radiography | 1 | 2012 | 6974 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 2003 | 1376 | 0.010 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2006 | 1318 | 0.010 |
Why?
|
Drug Combinations | 1 | 2006 | 2048 | 0.010 |
Why?
|
Databases, Factual | 1 | 2015 | 7966 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2010 | 2220 | 0.010 |
Why?
|
Doxorubicin | 1 | 2006 | 2224 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2008 | 2864 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2009 | 3210 | 0.010 |
Why?
|
Recurrence | 1 | 2011 | 8457 | 0.010 |
Why?
|
Vitamin D | 1 | 2012 | 3301 | 0.010 |
Why?
|
Decision Making | 1 | 2013 | 3931 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 2012 | 20588 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2021 | 15637 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2013 | 3198 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2005 | 20982 | 0.010 |
Why?
|
Fatty Acids | 1 | 2005 | 1807 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2014 | 7851 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2005 | 4107 | 0.010 |
Why?
|
Signal Transduction | 2 | 2011 | 23416 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2005 | 2455 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2014 | 4822 | 0.010 |
Why?
|
Stem Cells | 1 | 2009 | 3517 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2012 | 16952 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2005 | 2803 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2009 | 12474 | 0.010 |
Why?
|
Base Sequence | 1 | 2005 | 12404 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2005 | 3446 | 0.010 |
Why?
|
Hospitalization | 1 | 2014 | 10707 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2005 | 12052 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2005 | 11067 | 0.010 |
Why?
|
Algorithms | 1 | 2011 | 14025 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2012 | 17897 | 0.010 |
Why?
|
Adolescent | 1 | 2019 | 88298 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2005 | 20119 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2009 | 36415 | 0.000 |
Why?
|